Characteristics of prolactin-modulated LH induction of LH/hCG receptors. Transient inhibition of receptor induction following prolactin exposure

Differentiation of umbilical cord mesenchymal stem cells into steroidogenic cells in comparison to bone marrow mesenchymal stem cells

OBJECTIVES

Human umbilical cord can be obtained easily and it represents a non-controversial source of mesenchymal stem cells (MSCs) and umbilical cord Wharton's jelly-derived MSCs (UC-MSCs) have low immunogenicity. In this study, UC-MSCs were induced to become steroidogenic cells and compared to bone marrow-derived MSCs (BM-MSCs).

MATERIAL AND METHODS

UC-MSCs and BM-MSCs were induced to differentiate into steroidogenic cells by infection with adenovirus containing SF-1. Expression of steroidogenic mRNA was analysed by real-time RT-PCR and steroid secretion was detected by ELISA testing. Viability of differentiated cells was examined using cell counting kit-8 assay.

RESULTS

Both UC-MSCs and BM-MSCs expressed typical MSC markers and could differentiate into adipocytes, osteocytes and chondrocytes and both cell types had the potential to differentiate into steroidogenic cells after being infected with adenovirus containing SF-1 cDNA. However, UC-MSCs had significantly higher proliferative potential than BM-MSCs and differentiated UC-MSCs had significantly higher expression of all steroidogenic mRNAs tested over those of differentiated BM-MSCs; this included P450 side-chain cleavage enzyme, 3β-HSD, 17β-HSD type 3, LH-R, ACTH-R, P450c21 and CYP17. In addition, differentiated UC-MSCs secreted significantly more steroidogenic hormones than differentiated BM-MSCs, including testosterone and cortisol. Furthermore, differentiated UC-MSCs had significantly higher cell viability than differentiated BM-MSCs.

CONCLUSIONS

UC-MSCs had significantly higher potential of steroidogenic differentiation than BM-MSCs; thus, UC-MSCs could be favourable cells of choice for cell-based therapy for steroidogenic insufficiency compared to BM-MSCs.

Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer

Historically, hyperprolactinaemia has been considered of low toxicological relevance when detected in toxicity studies, and even mammary carcinogenesis induced in the rat by prolactin excess has been considered of no relevance to humans. However, recent findings from human epidemiology and molecular biology suggests that prolactin is a risk factor for human breast cancer, and probably prostate cancer. Therefore, this new evidence should be considered in the various decisions to develop and license a new drug or chemical if the compound causes hyperprolactinaemia. This emerging evidence suggests that prolactin can also be produced locally from human breast cancer cells, and that, regardless of source (ie, pituitary or autocrine/paracrine production from cancer cells), prolactin is mitogenic, stimulates proliferation and suppresses apoptosis in breast and prostate cancer cells. This review outlines the evidence that hyperprolactinaemia should be considered a toxicological adverse effect and concludes that prolactin-induced rodent mammary carcinogenesis is relevant to humans and is not species-specific. The effects of prolactin on the prostate gland are also discussed; hyperprolactinaemia may be an additional risk factor for prostate cancer and this also requires consideration in toxicological risk assessments. The implications of increased prolactin secretion as an adverse effect for regulatory toxicology of drugs and chemicals, and in high risk patients receiving therapeutic drugs with hyperprolactinaemic side effects, is discussed. Alteration of prolactin level is also a novel mechanism that requires consideration in endocrine disruption research, since both endogenous oestrogens and also xenoestrogens stimulate prolactin secretion or affect prolactin receptors.

In vitro effects of homologous prolactins on testosterone production by testes of tilapia (Oreochromis mossambicus)

The tilapia, Oreochromis mossambicus, produces two prolactins designated tPRL177 and tPRL188 to indicate the number of amino acid residues in each. The direct in vitro actions of tPRL177 and tPRL188 on basal and ovine luteinizing hormone (LH)-induced testosterone production in minced testes of courting and noncourting (bachelor) tilapia were examined. Courting males were housed with females and were used as soon as they built a spawning pit; noncourting males were housed with other males and were used when they appeared female-like in coloration. The in vitro culture system consisted of two phases. In phase 1 (0-10 hr), testicular tissue was incubated without (control) or with the tPRLs--both alone and together and in doses ranging from 0.5 to 32 microM. In phase 2 (10-16 hr), the culture medium was replaced with medium containing 6.25 microM (0.25 micrograms/ml) ovine LH. Testosterone production during both phases was determined by radioimmunoassay of the medium. The tPRLs stimulated testosterone production during phase 1 in courting males (by 25%) but not in noncourting males. Exposure to either or both tPRLs in phase 1 enhanced the response of testicular tissue from courting males to ovine LH (by 10%) and inhibited the response of minced testes taken from noncourting males (by 12%). This is the first evidence to demonstrate direct gonadal activity of homologous PRL in a teleost.